anti muscarinic drugs
PreclinicalSmall molecule
anti muscarinic drugs is one of 6 small molecule programs targeting Urgency Urinary Incontinence. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Urgency Urinary Incontinence
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Vesicare
AstellasApproved
Oxytrol
WWim Janssens
Approved
Sanctura Xr
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Botox
RRevance Therapeutics, Inc.
Preclinical
anti muscarinic drugs
CCairo University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Urgency Urinary Incontinence1 trial
Effect of Diaphragmatic Training on Urgency Urinary Incontinence in Postmenopausal Women
Completed·—·N/A·NCT06521008·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti muscarinic drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCairo University